secretagogue comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-22. Numbers and descriptions here follow the published literature rather than marketing material.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic pentapeptide | GHS-R1a agonist family |
| Receptor target | Ghrelin receptor (GHS-R1a) | G-protein-coupled receptor |
| Sequence length | Five amino acid residues | Includes non-natural residues |
| Primary reported output | Pulsatile growth hormone release | Observed in animal and early human work |
| Molecular formula | C38H49N9O5 | Corresponds to roughly 711.9 g/mol |
Quality claims for research peptides vary widely across suppliers. A certificate of analysis should list purity by chromatography, the mass found by spectrometry, and the analytical conditions used. Independent testing at a third-party laboratory is a common way to check identity and purity, because documents alone cannot confirm what is inside a vial. Purity figures describe the proportion of the target peptide among detected species, and they say nothing about biological activity or sterility.
Lyophilized ipamorelin powder is the form usually supplied for laboratory work. Kept dry, protected from light, and held at minus 20 degrees Celsius or below, it remains stable for extended periods, often measured in years. Once dissolved, the peptide degrades faster through hydrolysis, oxidation, and deamidation, so solutions are typically refrigerated and used within weeks. Repeated freeze-thaw cycles and exposure to alkaline conditions accelerate loss of the parent compound.
Reversed-phase high-performance liquid chromatography is the standard tool for assessing purity. Detection near 214 nanometers captures the peptide backbone, and the resulting chromatogram shows the main peak alongside related impurities. Electrospray ionization mass spectrometry confirms molecular mass and supports sequence verification. Common degradation products include oxidized residues, deamidated forms, and truncated fragments, each appearing as a distinct peak or shoulder in the trace.
=== Becky Conner === Rebecca "Becky" Conner (later Healy) is played by Lecy Goranson (Sarah Chalke in seasons 6–9). Born in 1975, Becky is the eldest of Roseanne and Dan's children. Becky is introduced to the series as a pre-teen, whose primary interests are centered around makeup, fashion, and boys. While she can be self-centered and occasionally acts spoiled, she actually is the least problematic of the Conner children, maintaining high grades and rarely causing issues for her parents beyond an occasional argument. However, as Becky matures, she grows moody and rebellious, resulting in her and a friend getting drunk on Roseanne and Dan's alcohol while alone in the Conner house. She has several clean-cut boyfriends, but soon prefers dating edgier, punkish guys that Roseanne and Dan disapprove of. They especially dislike her latest boyfriend (and future husband), Mark Healy, particularly after the young couple become sexually active. Becky's ultimate rebellion comes when she is seventeen and drops out of high school to elope with Mark and move to Minneapolis. In the year before her elopement, Becky's life was stressful. In addition to schoolwork and working as a cashier to save for a car, she was responsible for maintaining the household and tending her younger siblings while her parents worked long hours. Her breaking point came when she learnt her parents had used her college fund to pay household bills and, finally, when the family's bike shop failed, forcing her boyfriend Mark, who worked there, to move to Minneapolis for a new job.
=== Generic names === Buserelin is the generic name of the drug and its INNTooltip International Nonproprietary Name and BANTooltip British Approved Name, while buserelin acetate is its USANTooltip United States Adopted Name, BANMTooltip British Approved Name, and JANTooltip Japanese Accepted Name, buséréline is its DCFTooltip Dénomination Commune Française, and buserelina is its DCITTooltip Denominazione Comune Italiana. While under development by Hoechst AG, buserelin was also known as HOE-766.
Weapon-grade uranium obtained from nuclear weapons is diluted with uranium-238 and reused as fuel for nuclear reactors. Spent nuclear fuel forms radioactive waste, which mostly consists of uranium-238 and poses a significant threat to health and to the environment.
== Clinical significance == Mice with mutant carboxypeptidase E, Cpefat, display endocrine disorders like obesity and infertility. In some strains of mice, the fat mutation also causes hyperproinsulinemia in adult male mice, but this is not found in all strains of mice. The obesity and infertility in the Cpefat mice develop with age; young mice (<8 weeks of age) are fertile and have normal body weight. Peptide processing in Cpefat mice is impaired, with a large accumulation of peptides with C-terminal lysine and/or arginine extensions. Levels of the mature forms of peptides are generally reduced in these mice, but not eliminated. It is thought that a related enzyme (carboxypeptidase D) also contributes to neuropeptide processing and gives rise to the mature peptides in the Cpefat mice. Mutations in the CPE gene are not common within the human population, but have been identified. One patient with extreme obesity (Body Mass Index >50) was found to have a mutation that deleted nearly the entire CPE gene. This patient had intellectual disability (inability to read or write) and had abnormal glucose homeostasis, similar to mice lacking CPE activity. In obesity, high levels of circulating free fatty acids have been reported to cause a decrease in the amount of carboxypeptidase E protein in pancreatic beta-cells, leading to beta-cell dysfunction (hyperproinsulinemia) and increased beta-cell apoptosis (via an increase in ER stress).
In June 1911, while attending a conference in Stettin, Hahn met Edith Junghans (1887–1968), a student at the Royal School of Art in Berlin. They saw each other again in Berlin, and became engaged in November 1912. On 22 March 1913 the couple were married in Stettin, where Edith's father, Paul Ferdinand Junghans, was a high-ranking law officer and President of the City Parliament until his death in 1915. After a honeymoon at Punta San Vigilio on Lake Garda in Italy, they visited Vienna, and then Budapest, where they stayed with George de Hevesy. They had one child, Hanno Hahn, who was born on 9 April 1922. Hanno enlisted in the army in 1942, and served on the Eastern Front in World War II as a panzer commander. He lost an arm in combat. After the war he became an art historian and architectural researcher (at the Hertziana in Rome), known for his discoveries in the early Cistercian architecture of the 12th century. In August 1960, while on a study trip in France, Hanno died in a car accident, together with his wife and assistant Ilse Hahn née Pletz. They left a fourteen-year-old son, Dietrich Hahn. In 1990, the Hanno and Ilse Hahn Prize for outstanding contributions to Italian art history was established in memory of Hanno and Ilse Hahn to support young and talented art historians. It is awarded biennially by the Bibliotheca Hertziana – Max Planck Institute for Art History in Rome.
Sources: en.wikipedia.org
=== Bibliography === Arnheim, Daniel D. Dance Injuries: Their Prevention And Care. 3rd ed. Princeton, NJ: Princeton Book Company, 1991. Print. Ashley, Linda. Essential Guide to Dance. 2nd ed. London: Hodder & Stoughton, 2004. Print. ISBN 978-0340803202. Barratt, Marcia, et al. Foundations For Movement. Dubuque, IA: Wm. C. Brown Co., 1964. Print. Berardi, Gigi. Finding Balance. 2nd ed. Routledge, NY: Routledge, 2005. Print. ISBN 978-0415943390. Blakey, W P. Stretching Without Pain. Canada: Twin Eagles Educational & Healing Institute, 1994. Print. ISBN 978-1873017050. Como, William. Raoul Gelabert's anatomy for the dancer with exercises to improve technique and prevent injuries. New York: Danad, 1964; 51-57. ASIN B000XYUX4Q. Dilmen, Nevit. Stretching. 2009. Own Work. Wikimedia Commons. Web. 4 Dec. 2010. Franklin, Eric N. Conditioning for Dance. Champaign, IL: Human Kinetics, 2004. Print. FvS. Split, gymnastics. 2005. Own Work. Wikimedia Commons. Web. 4 Dec. 2010. Liedarback, "General considerations," p. 59. McCharles, Rick. Gymnast jumping on beam. 2008. https://www.flickr.com/photos/71035721@N00/2972933329. Wikimedia Commons. Web. 4 Dec. 2010. Pare, Caroline. Caroline Zhang in 2008 Skate Canada International. 2008. https://web.archive.org/web/20120724082853/http://everythingskating.com/. Wikimedia Commons. Web. 4 Dec. 2010. Reinking, Ann, and Linda Szmyd. The Dancer's Workout. London: Bantam Books, 1984. Print. Ryan, Allan J., and Robert E. Stephens, eds. The Healthy Dancer: Dance Medicine for Dancers. Princeton, NJ: Princeton Book Company, 1987. Print.
=== Pregnancy === Based on the limited data available, docetaxel appears to be safe in pregnancy if administered during the second and third trimesters; however, maternal and fetal risks should be weighed against benefits to determine the appropriate course of action. As with all chemotherapeutic agents, docetaxel administered to pregnant animals causes a variety of embryofetal toxicities, including death, when given during the period of organogenesis. Yet adequate studies investigating maternal and fetal effects in humans are lacking. One small systematic review that examined the use of taxanes to treat breast cancer in pregnancy showed that, out of 19 patients, only three congenital malformations occurred. Two cases of cerebral ventriculomegaly observed in the study were documented prior to the administration of chemotherapy, suggesting an alternate cause of congenital malformation. The third case involved pyloric stenosis in an infant whose mother received a combination regimen of docetaxel, doxorubicin, cyclophosphamide and paclitaxel; because the fetus was exposed to multiple drugs in utero, it remains difficult to identify docetaxel as the causative teratogenic agent. Further studies are needed to better assess the safety of docetaxel in pregnancy and determine appropriate dosing in pregnant women.
Brinckerhoff (1922), former CEO and chairman of Anaconda Copper, world's largest producer of copper Morris Schapiro (1923), investment banker, grandfather of painter Jacob Collins '86 and brother of art historian Meyer Schapiro '24 Lawrence Wien (1925), real estate magnate and philanthropist who owns the Empire State Building Francis Levien (1926), lawyer, director of Gulf and Western Industries, namesake of Levien Gymnasium Herbert Hutner (1928), private investment banker, attorney, and philanthropist; fourth husband of socialite Zsa Zsa Gabor Ivan Veit (1928), former executive vice president of The New York Times Nathan S. Ancell (1929), co-founder of furniture company Ethan Allen Ira D. Wallach (1929), head of Central National-Gottesman, the largest privately held marketer of paper and pulp products Benedict I. Lubell (1930), oilman, philanthropist Arthur Ross (1931), philanthropist, businessman; vice president of Central National-Gottesman; namesake of Arthur Ross Pinetum in Central Park Henry G. Walter Jr. (1931), businessman, former chairman and CEO of International Flavors & Fragrances and pioneer in aromatherapy Robert D. Lilley (1933), former president of AT&T 1972–1976 and the New Jersey Bell Telephone Company 1965–1970 Macrae Sykes (1933), investment banker, former chairman of the American Stock Exchange Robert David Lion Gardiner (1934), banker, landowner, 16th Lord of the manor of Gardiners Island, direct descendant of 17th-century English settler Lion Gardiner Arnold A. Saltzman (1936), businessman, diplomat, art collector, philanthropist George J.
== Classification == Wounds can be broadly classified as either acute or chronic based on time from initial injury and progression through normal stages of wound healing. Both wound types can further be categorized by cause of injury, wound severity/depth, and sterility of the wound bed. Several classification systems have been developed to describe wounds and guide their management. Some notable classification systems include the CDC's Surgical Wound Classification, the International Red Cross Wound Classification, the Tscherne classification, the Gustilo-Anderson classification of open fractures, and the AO soft tissue grading system.
A cannabinoid receptor modulator is a compound that bind to the cannabinoid receptors, which are receptors in the human body that regulate multiple physiological responses, including pain sensation, mood regulation, and appetite. The two main targets of cannabinoid receptors modulators are cannabinoid receptor 1 (CBR1) and cannabinoid receptor 2 (CBR2). By stimulating or inhibiting these receptors, the modulators can achieve different therapeutic effects, such as relieving pain, reducing vomiting, improving appetite and maintaining muscle tone. Dronabinol, nabiximol, cannabidiol and nabilone are cannabinoid receptor modulators marketed as drugs for various therapeutic uses. These drugs also share some common adverse effects, including dizziness, headache, alteration in mental state, and diarrhoea. Recent research studies have explored other therapeutic potentials of the modulators, such as the antitumor effect of cannabidiol. Other cannabinoid receptor modulators are also under investigations.
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family and acts as an agonist at the ghrelin receptor. It is handled as a laboratory research compound rather than a naturally occurring hormone.
Studies generally report growth hormone as the dominant output, with smaller or absent effects on adrenocorticotropic hormone and prolactin. The size of that separation depends on the assay and the dose examined, so it is best described as relative selectivity.
No natural source has been identified, and the molecule is produced by chemical synthesis. Its non-natural residues distinguish it from endogenous ghrelin even though both engage the same receptor.
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.